1Moschen AR, Kasser A, Enrich B, et al. Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties. J Immunol, 2007, 178: 1748-1758.
2Opstad TB, Pettersen A, Amesen H, et al. Circulating levels ofIL-18 are significantly influenced by the IL-18 + 183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol, 2011, 10:110-118.
3Caravaca F, Cerezo I. Insulin resistance in chronic kidney disease: its clinical characteristics and prognostic significance. Nefrologia, 2010, 30: 661-668.
4Mahmut IY, Mutlu S, Juan JC, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant, 2008, 23: 959-965.
5Fasshauer M, Waldeyer T, Seeqer J, et al. Serum levels of the adipokine Visfatin are increased in preeclampsia. Clin Endocrinol (Ox0, 2008, 69: 69-73.
6Oki K, Yamane K, Kanmei N, et al. Circuliating Visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf), 2007, 67: 796-800.
7Malyszko J, Malyszko JS, Pawlak K, et al. Visfatin and apelin, New adipocytokines and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci, 2008, 53: 32-36.
同被引文献29
1Geisthvel Franz. A comment on the European Society of Hu- man Reproduction and Embryology/American Society for Re- productive Medicine consensus of the polycystic ovarian syn- drome [ J ]. Reproductive Biomedicine Online, 2003,7 ( 6 ) : 602-605.
